Repros Therapeutics Inc. (Nasdaq: RPRX) 127% HIGHER; announced today that a study of its oral investogational product, enclomiphene citrate (Androxal) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE